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A B S T R A C T
Background and purpose: Recently, intermediate and high-risk prostate cancer patients have been treated in a
multicenter phase II trial with extremely hypofractionated prostate radiotherapy (hypo-FLAME trial). The
purpose of the current study was to investigate whether a 1.5 T magnetic resonance imaging guided linear
accelerator (MRI-linac) could achieve complex dose distributions of a quality similar to conventional linac state-
of-the-art prostate treatments.
Materials and methods: The clinically delivered treatment plans of 20 hypo-FLAME patients (volumetric modu-
lated arc therapy, 10MV, 5mm leaf width) were included. Prescribed dose to the prostate was 5×7Gy, with a
focal tumor boost up to 5× 10Gy. MRI-linac treatment plans (intensity modulated radiotherapy, 7MV, 7mm
leaf width, fixed collimator angle and 1.5 T magnetic field) were calculated. Dose distributions were compared.
Results: In both conventional and MRI-linac treatment plans, the V35Gy to the whole prostate was> 99% in all
patients. Mean dose to the gross tumor volume was 45 Gy for conventional and 44 Gy for MRI-linac plans,
respectively. Organ at risk doses were met in the majority of plans, except for a rectal V35Gy constraint, which
was exceeded in one patient, by 1 cc, for both modalities. The bladder V32Gy and V28Gy constraints were
exceeded in two and one patient respectively, for both modalities.
Conclusion: Planning of stereotactic radiotherapy with focal ablative boosting in prostate cancer on a high field
MRI-linac is feasible with the current MRI-linac properties, without deterioration of plan quality compared to
conventional treatments.
1. Introduction
External beam radiotherapy is one of the standard treatment options
for clinically localized prostate cancer, and is associated with long-term
disease control [1]. For prostate radiotherapy, extreme hypofractiona-
tion (≥5.0 Gy/fraction), or stereotactic body radiotherapy (SBRT), is
increasingly used, as the shortened treatment schedule is more con-
venient to the patient and potentially cost effective [2,3]. Multiple
single arm phase I and II extreme hypofractionation trials, and a recent
publication from the HYPO-RT-OC randomized phase II trial using
SBRT, showed low rates of severe toxicity and excellent biochemical
control for low and intermediate risk prostate cancer patients [4–8].
Given the high fraction dose, highly conformal dose distribution and
steep dose gradient seen with SBRT, accurate target volume definition
and dose delivery are crucial. The use of multiparametric (mp) mag-
netic resonance imaging (MRI) has improved target delineation for both
the prostate and organs at risk, due to its superior soft-tissue contrast
compared to computed tomography (CT) [9–11]. A previous rando-
mized phase III study showed that focal ablative boosting to the mp-
MRI visible tumor was feasible and not associated with increased
toxicity up to two years after treatment [12].
Prostate targeting accuracy based on position verification using fi-
ducial marker imaging is high [13]. However, treatment of prostate
cancer patients on a fully integrated MRI-linac system could increase
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treatment precision, further decrease the number of fractions required
and omit the need for invasive fiducial marker placement. These MRI-
linac systems allow an increased targeting accuracy as variations in
daily anatomy and deformations can be fully accounted for by daily
contour adjustment and replanning. Moreover, real-time imaging
during irradiation offers the potential to characterize and eventually
track prostate motion for MRI-guided radiotherapy, dose reconstruction
and, ultimately, real-time plan adaptation [14–18]. This could offer the
potential for reducing PTV margins, while capturing outliers in in-
trafractional motion in real time.
Currently, several systems integrating MRI with a linear accelerator
or cobalt system are commercially available or being developed
[14,19–22]. One of the clinically available systems is a high field (1.5
Tesla (T)) MRI-linac system, which has some technical differences
compared to standard clinical linacs (e.g. a fixed collimator angle,
larger leaf width, 7MV intensity modulated radiotherapy (IMRT) de-
livery only) [23]. Furthermore, the presence of a 1.5 T magnetic field
potentially may affect the dose distribution, e,g. due to the electron
return effect [24]. This effect is observed at boundaries between tissues
with large density differences and can induce an increase in local dose,
mainly when a single photon beam would be used. For MRI-guided
prostate radiotherapy this could particularly affect the dose distribution
near rectal air pockets. The present study is an R-IDEAL stage 0 study in
preparation of the clinical implementation of MRI-linac treatment for
prostate cancer [25]. R-IDEAL is a framework for systematic evaluation
and implementation of technical innovations in medical practice. Stage
0 studies include all preparations required before a technical innovation
can be clinically introduced.
The purpose of this study was to investigate whether a 1.5 T MRI-
linac system could achieve dose distributions of a quality similar to
conventional state-of-the-art prostate treatments in patients who are
treated with stereotactic whole prostate radiotherapy with focal abla-
tive dose escalation to the visible tumor.
2. Materials and methods
2.1. Patients
The present planning study involved 20 randomly selected clinically
delivered treatment plans from patients treated within the hypo-FLAME
study at the University Medical Center Utrecht. The hypo-FLAME study
was approved by the institutional review board and the informed
consent included approval to use the acquired data for future studies.
This study is a multicenter phase II study performed at the UMC
Utrecht, NKI-AvL Amsterdam, Radboudumc Nijmegen (The
Netherlands) and UZ Leuven (Belgium), which recently completed in-
clusion (n=100). The main objective is to determine whether ad-
ministering a focal simultaneously integrated SBRT boost (up to 50 Gy
in 5 weekly fractions) to the MRI-defined macroscopic tumor volume, in
addition to whole gland prostate SBRT (35 Gy), is clinically feasible and
associated with acceptable toxicity. For more information on the hypo-
FLAME study, see the Clinical Trials Registry (NCT02853110).
2.2. Radiotherapy simulation and contouring
Before radiotherapy treatment, gold fiducial markers were inserted
and a multiparametric (mp) MRI (T2 weighted, diffusion weighted
imaging (DWI) and dynamic contrast enhanced (DCE) sequences) and
radiotherapy planning CT scan were performed. Patients were planned
and treated in supine position. Patients were advised to have a com-
fortably full bladder prior to radiotherapy planning and each treatment
fraction. The MRI protocol is consistent with European Society of
Urogenital Radiology (ESUR) guidelines [26]. The planning CT scan
was registered with the MRI.
The tumor nodules as visible on mpMRI were contoured as gross
tumor volume (GTV). In five patients, two separate GTVs were
contoured and planned for both planning modalities, resulting in 25
GTVs eligible for analysis. The whole prostate gland was considered
clinical target volume (CTV; including the GTV+4mm margin, ex-
cluding organs at risk). The seminal vesicles were contoured at the
discretion of the treating physician. The margin from the CTV contour
around the prostate to planned target volume (PTV) was 4mm based on
earlier experience with volumetric modulated arc therapy (VMAT)
prostate SBRT [27]. The rectum was contoured from the external
sphincter of the anus to the rectosigmoid flexure, the anal canal was
contoured from the external sphincter up to the internal sphincter
(typically 3 cm). The penile bulb, prostatic urethra and the bladder
were also delineated. The small bowel was only contoured when lo-
cated near the PTV.
2.3. Treatment planning and dose constraints
MRI-linac plans were created for the Unity linac (Elekta AB) which
integrates a 1.5 T MR scanner with a 7MV linac mounted on a ring
gantry. Beam characteristics and the presence of a magnetic field and
cryostat were all accounted for in the treatment planning software. In
order to fully account for the influence of the electron-return-effect in
case of rectal gas, no density override was applied to the rectum in the
MRI-linac treatment plans. Beam characteristics are described in detail
by Woodings et al. and first patient treatments were performed in May
2017 [14,28]. The most important differences of the MRI-linac system
compared to our conventional linac are (1) the 1.5 T magnetic field, (2)
the 7mm leaf width at isocenter, (3) the fixed collimator angle with
leaves traveling in craniocaudal direction, (4) the 7MV flattening filter
free beam energy, (5) the cryostat and body-coil the beam needs to
pass, (6) the fixed table top to isocenter distance of 13 cm and (7) the
step-and-shoot IMRT delivery. Therefore, it was not a priori evident
that dose distributions on the MRI-linac could match those on the
conventional machines.
The MRI-linac IMRT plans were created in the clinically commis-
sioned Monaco TPS (v5.19) using a 7 beam setup. The minimum seg-
ment area and width were 1.5 cm2 and 0.5 cm, respectively. The
minimum number of monitor units per segment was 5, with a maximum
of 125 segments. The calculation grid spacing was 3mm with a statis-
tical dose uncertainty per control point of 3% and<1% per voxel.
Patients were treated on conventional Agility linacs (5mm MLC leaf
width) using 10MV VMAT plans, dual full arc, created in the Monaco
TPS (Elekta AB). The maximum number of control points per arc was
144. The minimum segment width was 0.5 cm. De grid spacing was
3mm, with a statistical uncertainty per control point of 8% and<1%
per voxel. Dose to medium was applied for both planning techniques.
For comparison of the Agility linac and MRI-linac plans, dose–vo-
lume histograms (DVHs) for all volumes of interest and corresponding
dose parameters were calculated. Planning constraints for coverage of
the target volumes and organs at risk (OAR) are depicted in Table 1.
OAR constraints were based on the pHART6 and 7 studies with addi-
tional dose constraints added by the hypo-FLAME study group [29]. Not
exceeding OAR constraints was considered of higher importance than
boosting the GTV, therefore, GTV doses were as high as achievable (up
to 50 Gy) while respecting the OAR constraints (iso-toxic boosting).
2.4. Data analysis
MRI-linac dose distributions were compared to those of the corre-
sponding clinically delivered conventional treatment plans. Median
values on coverage, high dose volumes and OAR doses were evaluated.
Non-parametric testing was performed to compare the paired variables
by performing a Wilcoxon signed-rank test by using IBM SPSS Statistics
20 (Chicago, IL, USA) with a significance level of α below 0.05.
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3. Results
Comparable treatment plans for stereotactic prostate radiotherapy
with focal ablative boosting could be created for the conventional linac
and MRI-linac. The dose as prescribed to the whole prostate gland was
adequately covered for both treatment modalities (Table 2). Regarding
the GTV boost, the median V40Gy was> 99% for both planning
modalities. The corresponding median dose to the GTV boost was 45 Gy
(range 43–51) for conventional plans and 44 Gy (range 42–49 Gy) for
MRI-linac plans, respectively. The V52Gy (104%) was exceeded in two
patients on conventional plans by 1 cc at most. In MRI-linac plans, V52
Gy was 0.2 cc in one patient. OAR constraints were not exceeded in
these particular patients. For the rectum, bladder, urethra and bowel,
no clinically relevant differences in median dose constraints were ob-
served between planning modalities, although some differences were
statistically significant. For rectal dose, the V35Gy was exceeded in one
conventionally planned patient by 1.2 cc and for the MRI-linac plan by
0.6 cc. In one other patient, the V32Gy for the bladder was slightly
exceeded by 3% for the MRI-linac plan, but not for the conventional
plan. For a patient with a Bricker deviation and a native (empty)
bladder in situ, the V32Gy and V28Gy for the native bladder were ex-
ceeded by 11% and 17% respectively for the conventional plan and
14% and 19% for the MRI-linac plan, which was clinically accepted. For
another patient the penile bulb dose was exceeded for both modalities,
which was clinically accepted. Fig. 1 shows a sagittal view of a con-
ventional and MRI-linac treatment plan for a hypo-FLAME patient with
a large amount of rectal air.
The average number of monitor units and segments was 2970 and
226 for conventional VMAT plans and 2975 and 120 for MRI linac
IMRT plans, respectively.
4. Discussion
The results of this study show that stereotactic treatment planning
with an ablative tumor boost in prostate cancer on a high field MRI-
linac is comparable to conventional VMAT treatment planning in terms
of dose parameters. In one patient, one bladder constraint (V32Gy) was
exceeded slightly for the MRI-linac plan and not for the conventional
plan. For the other OAR exceeding’s, the constraints were exceeded for
both planning modalities. As these particular constraints were chal-
lenging to meet for both planning techniques, constraint violation was
not considered the result of differences in planning properties or the use
of either an IMRT or VMAT technique but due to the challenge of SBRT
with focal boost planning in general. Therefore, no clinically relevant
Table 1
Target volume dose prescription and OAR constraints for the hypo-FLAME
study.
Target coverage
GTV_5000 V40Gy > 99% (if possible)
Dmax V52Gy (if possible)
CTV_3500 V35Gy > 99%
PTV_3325 V33.25 Gy > 99%
PTV_3000 V30Gy > 99%
OAR constraints
Rectum Dmax < 40 Gy
V35Gy 2 cc (if possible < 1 cc)
V32Gy≤15%
V28Gy≤20%
Rectum_PRV2mm* Dmax < 42 Gy
Bladder V42Gy < 1 cc
V37Gy < 5 cc
V32Gy≤15%
V28Gy≤20%
Urethra Dmax < 42 Gy
Urethra_PRV2mm* Dmax < 42 Gy
Small bowel# Dmax < 35 Gy
V19.5 < 5 cc
Penile bulb V20Gy≤90%
Femoral head V28Gy≤5%
Dose constraints pHART studies and hypo-FLAME group * Planned risk
volume (PRV) # Only contoured when adjacent to PTV.
Table 2
Dosimetric parameters for conventional and MRI-linac treatment plans.
Conventional VMAT MRI-linac IMRT
median range median range p value
Target coverage
GTV_5000 V40Gy (%) 99.8 97.5–100 99.9 97.7–100 0.41
V52Gy (cc) 0.0 0.0–1.1 0.0 0.0–0.2 0.07
Mean dose (Gy) 45.1 43.34–50.6 44.1 42.31–48.6 < 0.01
CTV_3500 V35Gy (%) 99.9 99.4–100 99.9 99.2–100 0.60
PTV_3325 V33.25 Gy (%) 99.1 98.2–99.8 99.7 98.7–100 <0.01
PTV_3000 V30Gy (%) 99.1 98.5–100 99.9 99.6–100 <0.01
OAR constraints
Rectum Dmax (Gy) 37.7 35.90–40.9 36.9 36.0–41.2 0.04
V35Gy (cc) 1.0 0.1–3.2 0.8 0.1–2.6 < 0.01
V32Gy (%) 5.0 2.7–7.5 4.8 2.9–9.2 0.94
V28Gy (%) 10.4 6.1–17.0 9.9 5.3–16.0 0.88
Rectum_PRV2mm Dmax (Gy) 40.4 37.10–42.2 39.1 37.1–42.0 0.02
Bladder V42Gy (cc) 0.0 0.0–0.2 0.0 0.0–0.4 0.44
V37Gy (cc) 1.5 0.0–4.9 0.4 0.0–5.0 0.17
V32Gy (%) 7.1 2.1–26.0 8.3 2.1–28.9 < 0.01
V28Gy (%) 11.0 4.9–37 12.5 4.7–39.3 < 0.01
Urethra Dmax (Gy) 40.5 38.6–41.2 40.4 38.4–41.7 0.41
Urethra_PRV2mm Dmax (Gy) 41.8 41.3–42.1 41.8 40.7–42.6 0.55
Bowel Dmax (Gy) 1.7 0.7–12.8 2.7 1.3–11.2 0.03
V19.5 (cc) 0.0 0.0 0.0 0.0
Penile bulb V20Gy (%) 5.4 0–97.3 12.7 0–100 <0.01
Femoral heads V28 (%) 0.0 0.0–0.0 0.0 0.0–0.0
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influences of the larger leaf width, 7 MV IMRT technique or electron-
return-effect in MRI-linac treatment plans were observed.
As SBRT with focal boost treatment planning on a high field MRI-
linac is feasible for prostate cancer, it allows further exploitation of
possible advantages of adaptive radiotherapy on the current clinical
high field MRI-linac machine. Its fundamental assets are both daily and
continuous intrafraction soft tissue imaging [14,30]. Daily MRI can be
used for soft-tissue based position verification or for contour adjustment
and replanning [23]. Real-time imaging during irradiation, combined
with future options for active motion compensation like gating or even
online dose reconstruction and real-time plan adaptation, offers the
potential for future PTV margin reduction and OAR sparing [14–18].
This could eventually allow for further hypofractionation in prostate
radiotherapy.
In this study, an identical 5mm PTV margin was used for both
conventional VMAT and MRI-linac treatment plans. As the dose rate of
the MRI-linac is lower than on our conventional linacs (420 vs.
600MU/min), and IMRT is used instead of VMAT, the treatment times
on an MRI-linac will be longer. This might have a substantial effect on
intrafractional motion, which could acquire PTV margin adjustments.
For this study, in which the purpose was only to investigate the influ-
ence of the magnetic field on treatment planning, PTV margins were
deliberately kept identical. Moreover, with the future MRI-linac possi-
bilities for online motion compensation and replanning, as described
above, the intrafractional motion during the prolonged treatment time
can be actively compensated for. However, before performing stereo-
tactic prostate radiotherapy on the MRI-linac, dealing with intrafraction
motion based on cine MRI needs to be further developed [31].
In addition to beam-on time, the total duration of a treatment ses-
sion on the current MRI-linac can be substantially longer than on a
regular linac. The different stages during an MRI-linac treatment ses-
sion using a so-called ‘adapt to shape’ workflow consist of MRI-acqui-
sition, image registration, contour propagation and adjustment, re-
planning, acquisition of a second MRI for position verification, dose
check, radiotherapy delivery and intrafraction- and post-treatment MRI
acquisition [14,23,32]. Treatment session times of clinically delivered
MRI-linac treatments in patients with lymph node metastases were ty-
pically within 60min, which we also would expect for prostate SBRT
[32]. Future treatment session times are expected to decrease, as they
are subject to experience and technical developments like shorter
computational times with increasing computer power, smarter algo-
rithms, even faster MRI, and improved contour propagation.
The purpose of this study was to evaluate the effect of the magnetic
field on radiotherapy treatment planning. As the electron return effect
is particularly evident at air-tissue boundaries, no density override to
the rectum was applied, to fully account for the effect of rectal gas
pockets. Air cavities can appear or disappear during irradiation. The
effect of intrafractional nonstationary spherical air cavities, within a
target volume, on IMRT dose delivery in the presence of a magnetic
field was studied in a phantom study by Bol et al. [33]. They found
single voxel dose differences up to 5%. These findings were confirmed
by a MRI-linac planning study in rectal cancer patients by Uilkema et al.
[34]. Both of these studies investigated air cavities within the target
volume and not adjacent to the target, as will be the case in prostate
cancer treatment. However, MRI-guidance during treatment would
allow for detection of air cavity changes and adaptive strategies.
The time spent on pre-treatment treatment planning was not mea-
sured. Treatment planning time for MRI-linac was prone to a learning
curve and is highly dependent on the calculation power of the hard-
ware. In our current clinical practice, MRI-linac plans can be derived
within a time frame comparable to clinical VMAT treatment plans.
This was the first study investigating plan equivalency between
conventional and high field MRI-linac treatment plans for extremely
hypofractionated prostate cancer radiotherapy with a focal boost. Our
findings are in line with studies investigating this effect in conventional
or moderately hypofractionated prostate radiotherapy [35–37]. Also for
other tumor sites, as lung, (partial) breast, rectum and pancreas, the
influence of the magnetic field has been evaluated and resulted in small
dose differences and clinically acceptable plans [34,35,38–43].
A strength of the study is that the data of 20 clinically delivered
VMAT SBRT treatment plans from the hypo-FLAME study were used.
Consequently, clinically derived contours and clinically applied con-
straints of target volumes and OARs were used to create MRI-linac
treatment plans. In this study, IMRT plans were compared to VMAT
plans. This difference in technique was accepted deliberately as the
purpose of the study was to investigate plan equivalency between MRI-
linac (which offers step-and-shoot IMRT) and the current standard of
care in our institute (which is VMAT).
Additional studies have been initiated to determine the effect of
online adaptive planning on the MRI-linac on target coverage and OAR
dose and, subsequently, on biochemical disease free survival and toxi-
city. Multicenter MRI-guided feasibility studies in an international re-
search consortium have started using a 1.5 T MRI-linac for prostate
cancer patients and MRI-guided treatment will continuously be
Fig. 1. Sagittal view of a patient with air pockets in the rectum (a) VMAT plan on a conventional linac (b) IMRT plan on an MRI-linac. Delineated target structures:
pink PTV_3325, red GTV_5000, white CTV_3000, brown PTV_3000. Delineated organs at risk: light blue rectum with anal canal, dark blue bladder, green small bowel,
yellow urethra, white penile bulb. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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improved within the context of the R-IDEAL framework.
In conclusion, planning of stereotactic ablative focal boosting in
prostate cancer on a high field MRI-linac is feasible, without dete-
rioration of plan quality compared to treatment on a conventional linac.
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